<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Myth</title>
	<atom:link href="http://www.tapanray.in/tag/myth/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>High Innovation-Cost Makes Cancer Drugs Dear: A Fragile Argument?</title>
		<link>http://www.tapanray.in/high-innovation-cost-makes-cancer-drugs-dear-a-fragile-argument/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=high-innovation-cost-makes-cancer-drugs-dear-a-fragile-argument</link>
		<comments>http://www.tapanray.in/high-innovation-cost-makes-cancer-drugs-dear-a-fragile-argument/#comments</comments>
		<pubDate>Mon, 18 Sep 2017 00:00:55 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[17]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[argument]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[bust]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Chief]]></category>
		<category><![CDATA[CM]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[dear]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[expensive]]></category>
		<category><![CDATA[fragile]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[innovation-cost]]></category>
		<category><![CDATA[intensive]]></category>
		<category><![CDATA[jeopardizing]]></category>
		<category><![CDATA[Keytruda]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[Maharashtra]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Myth]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[policymakers]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Senate]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technological]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[tribe]]></category>
		<category><![CDATA[unaffordable]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8417</guid>
		<description><![CDATA[Cancer is a major cause of high morbidity and mortality in India, just many other countries, according to a report of the World Health Organization (W.H.O). While deaths from cancer worldwide are projected to continue to rise to over 1.31 &#8230; <a href="http://www.tapanray.in/high-innovation-cost-makes-cancer-drugs-dear-a-fragile-argument/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/high-innovation-cost-makes-cancer-drugs-dear-a-fragile-argument/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does Drug Pricing Freedom Benefit Patients in A Free-Market Economy?</title>
		<link>http://www.tapanray.in/does-drug-pricing-freedom-benefit-patients-in-a-free-market-economy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-drug-pricing-freedom-benefit-patients-in-a-free-market-economy</link>
		<comments>http://www.tapanray.in/does-drug-pricing-freedom-benefit-patients-in-a-free-market-economy/#comments</comments>
		<pubDate>Mon, 13 Oct 2014 00:00:40 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[(NCPA)]]></category>
		<category><![CDATA[Committee on Oversight and Government Reform]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Cummings]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[Dr. Reddy’s Laboratories]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[free-market]]></category>
		<category><![CDATA[freedom]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Myth]]></category>
		<category><![CDATA[National Community Pharmacists Association]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Senator Bernard Sanders]]></category>
		<category><![CDATA[Sun Pharma]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[update]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Zydus Cadila]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6094</guid>
		<description><![CDATA[A 2010 USFDA update titled ‘Generic Competition and Drug Prices’ highlighted that generic competition is intimately associated with lower drug prices, and the entry of the second generic competitor is associated with the largest price reduction. The agency found that &#8230; <a href="http://www.tapanray.in/does-drug-pricing-freedom-benefit-patients-in-a-free-market-economy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-drug-pricing-freedom-benefit-patients-in-a-free-market-economy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Higher The Healthcare  Spend, Better The Healthcare Performance: A Myth?</title>
		<link>http://www.tapanray.in/higher-the-healthcare-spend-better-the-healthcare-performance-a-myth/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=higher-the-healthcare-spend-better-the-healthcare-performance-a-myth</link>
		<comments>http://www.tapanray.in/higher-the-healthcare-spend-better-the-healthcare-performance-a-myth/#comments</comments>
		<pubDate>Mon, 23 Jun 2014 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[better]]></category>
		<category><![CDATA[BRIC]]></category>
		<category><![CDATA[commonwealth]]></category>
		<category><![CDATA[eleven]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[Fund]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[higher]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[linear]]></category>
		<category><![CDATA[Myth]]></category>
		<category><![CDATA[nations]]></category>
		<category><![CDATA[New Zealand]]></category>
		<category><![CDATA[optimal]]></category>
		<category><![CDATA[performance]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relationship]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[spend]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[wealthy]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5542</guid>
		<description><![CDATA[It is generally believed, higher the per-capita expenditure of healthcare, better is the overall ‘healthcare performance’ of a nation. However, this myth has recently been busted by a new study, the take-home message of which would be quite relevant for &#8230; <a href="http://www.tapanray.in/higher-the-healthcare-spend-better-the-healthcare-performance-a-myth/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/higher-the-healthcare-spend-better-the-healthcare-performance-a-myth/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Regulatory Data Protection (RDP) and its need in India: The Myth versus Reality</title>
		<link>http://www.tapanray.in/regulatory-data-protection-rdp-and-its-need-in-india-the-myth-versus-reality/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=regulatory-data-protection-rdp-and-its-need-in-india-the-myth-versus-reality</link>
		<comments>http://www.tapanray.in/regulatory-data-protection-rdp-and-its-need-in-india-the-myth-versus-reality/#comments</comments>
		<pubDate>Tue, 08 Dec 2009 07:13:04 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[compliant]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[its]]></category>
		<category><![CDATA[Myth]]></category>
		<category><![CDATA[need]]></category>
		<category><![CDATA[pharmacuticals]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[reality]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[secret]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[versus]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=703</guid>
		<description><![CDATA[THE MYTH: An attempt to delay the launch of Indian generics: Some in India feel that Regulatory Data Protection (RDP), is a deliberate attempt by the innovator companies to delay the launch of the generic equivalent of patented products in &#8230; <a href="http://www.tapanray.in/regulatory-data-protection-rdp-and-its-need-in-india-the-myth-versus-reality/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/regulatory-data-protection-rdp-and-its-need-in-india-the-myth-versus-reality/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Regulatory Data Protection (RDP) and its need in India: The Myth versus Reality</title>
		<link>http://www.tapanray.in/regulatory-data-protection-rdp-and-its-need-in-india-the-myth-versus-reality-2/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=regulatory-data-protection-rdp-and-its-need-in-india-the-myth-versus-reality-2</link>
		<comments>http://www.tapanray.in/regulatory-data-protection-rdp-and-its-need-in-india-the-myth-versus-reality-2/#comments</comments>
		<pubDate>Mon, 07 Dec 2009 01:00:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[compliant]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[its]]></category>
		<category><![CDATA[Myth]]></category>
		<category><![CDATA[need]]></category>
		<category><![CDATA[pharmacuticals]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[reality]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[secret]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[versus]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=706</guid>
		<description><![CDATA[THE MYTH: An attempt to delay the launch of Indian generics: Some in India feel that Regulatory Data Protection (RDP), is a deliberate attempt by the innovator companies to delay the launch of the generic equivalent of patented products in &#8230; <a href="http://www.tapanray.in/regulatory-data-protection-rdp-and-its-need-in-india-the-myth-versus-reality-2/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/regulatory-data-protection-rdp-and-its-need-in-india-the-myth-versus-reality-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
